1. Slide 8 - 115,000 chronic HCV patients in the Nordics; 3,000 receive treatment per year. 2. Slide 16 - Analysts estimate peak sales of TMC435 as $2-$4B dollars 3. Slide 18 - They also have an NS5A program at LO stage (assume that's lead optimization) along with other nukes 4. Slide 20 - TMC435 patent life extends to 2026 and 2028